Researchers have demonstrated safe, non-invasive deflation of the Smart tracheal occlusion (Smart-TO) balloon using magnetic resonance, according to a first-in-human phase 1 study published in The Lancet. The device is designed for fetoscopic endoluminal tracheal occlusion (FETO) in cases of congenital diaphragmatic hernia (CDH). The new approach spares patients a second intrauterine procedure.
CDH is a birth defect where abdominal organs push into the chest, compressing the lungs. Antenatal treatment for moderate or severe cases has evolved from experimental to evidence-based for selected high-risk pregnancies, the commentary notes. This refinement addresses a key limitation of conventional FETO: the need for invasive balloon removal.
The single-arm, open-label trial assessed magnetic resonance-induced balloon deflation and short-term safety. Results showed effective deflation, supporting the procedure's short-term safety profile. These findings constitute an important advance in fetal surgery, the authors state.
Eliminating the second intervention could reduce procedural risks for both mother and fetus. If confirmed in larger trials, the Smart-TO device may lower complication rates and broaden access to FETO therapy. The next step involves validating efficacy across more diverse patient populations.
The commentary highlights that this is a potential practice-changing refinement, though phase 1 data are limited to short-term outcomes. Longer follow-up and comparative studies are needed to fully establish benefits over standard care.